S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
NASDAQ:VRDN

Viridian Therapeutics News Headlines

$13.52
+2.96 (+28.03%)
(As of 05/13/2022 06:55 PM ET)
Add
Compare
Today's Range
$10.75
$14.16
50-Day Range
$9.55
$20.44
52-Week Range
$9.47
$22.00
Volume
500,900 shs
Average Volume
135,438 shs
Market Capitalization
$367.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.12
Get Viridian Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for VRDN and its competitors with MarketBeat's FREE daily newsletter.

Media Mentions By Week

Viridian Therapeutics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

VRDN
News Sentiment

-0.29

0.48

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

VRDN Articles
This Week

11

1

VRDN Articles
Average Week



Viridian Therapeutics (NASDAQ:VRDN) News Headlines Today

SourceHeadline
marketwatch.com logoViridian Therapeutics Shares Soar 32% Following Drug Trial Updates, 1Q Results
marketwatch.com - May 13 at 4:10 PM
benzinga.com logoViridian Therapeutics: Q1 Earnings Insights
benzinga.com - May 13 at 1:39 AM
seekingalpha.com logoViridian Therapeutics GAAP EPS of $0.98, revenue of $0.22M
seekingalpha.com - May 13 at 1:39 AM
nasdaq.com logoViridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Lags Revenue Estimates
nasdaq.com - May 13 at 1:39 AM
seekingalpha.com logoViridian Therapeutics, Inc. (VRDN) CEO Jonathan Violin on Q1 2022 Results - Earnings Call Transcript
seekingalpha.com - May 13 at 1:39 AM
finance.yahoo.com logoViridian Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Updates
finance.yahoo.com - May 13 at 1:39 AM
MarketBeat logoJonathan Violin Sells 30,000 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) Stock
americanbankingnews.com - May 6 at 5:08 AM
finance.yahoo.com logoViridian Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call on May 12, 2022
finance.yahoo.com - May 3 at 10:26 AM
MarketBeat logoReviewing Viridian Therapeutics (NASDAQ:VRDN) & Sera Prognostics (NASDAQ:SERA)
americanbankingnews.com - April 23 at 1:46 AM
finance.yahoo.com logoViridian Therapeutics to Participate in The 21st Annual Needham Virtual Healthcare Conference on April 14
finance.yahoo.com - April 6 at 12:35 PM
finance.yahoo.com logoViridian Therapeutics Doses First Subject in First-in-Human Clinical Trial Evaluating VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease
finance.yahoo.com - March 21 at 5:52 PM
finance.yahoo.com logoViridian Therapeutics to Participate in 32nd Annual Oppenheimer Healthcare Conference on March 15
finance.yahoo.com - March 14 at 7:31 PM
finance.yahoo.com logoOppenheimer Bets on These 2 Stocks; Sees Over 40% Upside Potential
finance.yahoo.com - March 14 at 7:31 PM
seekingalpha.com logoViridian Therapeutics GAAP EPS of -$1.32, revenue of $0.21M
seekingalpha.com - March 12 at 2:39 AM
benzinga.com logoViridian Therapeutics: Q4 Earnings Insights
benzinga.com - March 10 at 7:59 PM
finance.yahoo.com logoViridian Therapeutics Reports Fourth Quarter And Full Year 2021 Financial Results And Provides Corporate Updates
finance.yahoo.com - March 10 at 7:59 PM
finance.yahoo.com logoStrong week for Viridian Therapeutics (NASDAQ:VRDN) shareholders doesn't alleviate pain of five-year loss
finance.yahoo.com - March 10 at 2:56 PM
finance.yahoo.com logoViridian Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Host Investor Conference Call on March 10, 2022
finance.yahoo.com - March 3 at 7:57 PM
nasdaq.com logoPliant Therapeutics, Inc. (PLRX) Reports Q4 Loss, Lags Revenue Estimates
nasdaq.com - February 28 at 10:13 PM
finance.yahoo.com logoViridian Therapeutics to Participate in the SVB Leerink 2022 Global Healthcare Conference on February 18
finance.yahoo.com - February 14 at 9:49 AM
markets.businessinsider.com logoViridian Therapeutics To Test Next-Gen IGF-1R Antibody In Thyroid Eye Disease
markets.businessinsider.com - January 31 at 2:56 PM
seekingalpha.com logoViridian wins FDA OK to start clinical trial for thyroid eye disease candidate
seekingalpha.com - January 31 at 9:55 AM
finance.yahoo.com logoViridian Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Development of VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease
finance.yahoo.com - January 31 at 9:55 AM
benzinga.com logoViridian Therapeutics Submits Investigational New Drug Application For VRDN-002 To FDA
benzinga.com - January 4 at 10:32 AM
finance.yahoo.com logoViridian Therapeutics Submits Investigational New Drug Application for VRDN-002 to the U.S. Food and Drug Administration
finance.yahoo.com - January 4 at 10:32 AM
finance.yahoo.com logoViridian Therapeutics Announces First Subject Dosed in Phase 1/2 Clinical Trial of VRDN-001 for Thyroid Eye Disease (TED)
finance.yahoo.com - December 20 at 10:06 AM
finance.yahoo.com logoViridian Therapeutics Announces First Subject Dosed in Phase 1/2 Clinical Trial of VRDN-001 for Thyroid Eye Disease (TED)
finance.yahoo.com - December 20 at 10:06 AM
finance.yahoo.com logoViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
finance.yahoo.com - November 30 at 8:50 AM
finance.yahoo.com logoViridian Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for VRDN-001, an IGF-1R Antibody for the Treatment of Thyroid Eye Disease (TED)
finance.yahoo.com - November 15 at 10:01 AM
finance.yahoo.com logoViridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Misses Revenue Estimates
finance.yahoo.com - November 5 at 1:39 AM
finance.yahoo.com logoViridian Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Updates
finance.yahoo.com - November 4 at 8:38 PM
finance.yahoo.com logoViridian Therapeutics to Present at Upcoming Investor Conferences
finance.yahoo.com - November 3 at 7:52 PM
msn.com logoBRIEF-Viridian Therapeutics Inc Submits Investigational New Drug Application For VRDN-001 To The U.S. Food And Drug Administration
msn.com - October 14 at 8:25 AM
finance.yahoo.com logoViridian Therapeutics Submits Investigational New Drug Application for VRDN-001, an IGF-1R antibody for the treatment of Thyroid Eye Disease, to the U.S. Food and Drug Administration
finance.yahoo.com - October 14 at 8:25 AM
realmoney.thestreet.com logoViridian Therapeutics, Inc. (VRDN)
realmoney.thestreet.com - October 14 at 3:25 AM
finance.yahoo.com logoViridian Therapeutics to Present Preclinical Data on VRDN-001 and VRDN-002 at the 90th Annual Meeting of the American Thyroid Association
finance.yahoo.com - September 30 at 8:10 AM
insidertrades.com logoLast Week’s 3 Most Intriguing Insider Buys
insidertrades.com - September 30 at 7:00 AM
finance.yahoo.com logoViridian Therapeutics Announces Closing of Public Offering of Shares of Common Stock and Preferred Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
finance.yahoo.com - September 23 at 5:25 PM
marketwatch.com logoViridian Therapeutics Shares Rise 17% After Public Offering Prices
marketwatch.com - September 21 at 11:34 PM
finance.yahoo.com logoViridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock and Preferred Stock
finance.yahoo.com - September 21 at 8:33 AM
msn.com logoBRIEF-Viridian Therapeutics Announces Proposed Public Offering Of Common Stock And Preferred Stock
msn.com - September 20 at 6:58 PM
finance.yahoo.com logoViridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
finance.yahoo.com - September 20 at 6:58 PM
finance.yahoo.com logoStrong week for Viridian Therapeutics (NASDAQ:VRDN) shareholders doesn't alleviate pain of three-year loss
finance.yahoo.com - August 23 at 3:38 PM
nasdaq.com logoShareholders in Viridian Therapeutics (NASDAQ:VRDN) have lost 87%, as stock drops 15% this past week
nasdaq.com - August 12 at 5:32 PM
finance.yahoo.com logoViridian Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Updates
finance.yahoo.com - August 11 at 11:33 AM
finance.yahoo.com logoViridian Therapeutics to Participate in the Wedbush PacGrow Healthcare Virtual Conference
finance.yahoo.com - August 5 at 9:43 AM
finance.yahoo.com logoViridian Therapeutics Appoints Kristian Humer as Chief Financial Officer and Chief Business Officer
finance.yahoo.com - July 26 at 12:31 PM
sg.finance.yahoo.com logoPlaza Premium Cuts Ties With Priority Pass. Here’s What It Means For You.
sg.finance.yahoo.com - July 15 at 6:16 PM
finance.yahoo.com logoViridian Therapeutics Appoints Jennifer Moses, CPA to the Board of Directors and as Chair of the Audit Committee
finance.yahoo.com - July 15 at 6:16 PM
finance.yahoo.com logoViridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
finance.yahoo.com - July 14 at 8:59 AM
Get Viridian Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for VRDN and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 5/16/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.